Exelixis | EXEL - Pre Tax Profit


Exelixis reported $252.69M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Agios Pharmaceuticals USD -109.06M 5.62M Dec/2025
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
AstraZeneca USD 3.24B 117M Sep/2025
Bayer EUR -1.16B 735M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Eisai JPY 22B 7.47B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Exelixis USD 252.69M 275K Dec/2025
Genmab DKK 55M 427M Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 389.94M 92.37M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Nektar Therapeutics USD -37.05M 15.27M Sep/2024
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.64B 445M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Sanofi EUR -1.16B 6.23B Dec/2025
Takeda JPY 133.86B 105.69B Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Xencor USD -4.27M 1.76M Dec/2025